Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk ...

Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

As obesity rates rise in India and GLP-1 drugs gain traction despite cost and safety concerns, Mumbai-based gut health ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss., ...

Skinny jab? Try skinny juice. For centuries, it’s been enjoyed by people in South America — and it’s long been linked to ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from ...

At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results from a study by Fretz et al., ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.